RE:RE:RE:RE:Big pharma is set to keep signing bigger deals in 2024November 14, 2024 - BioNTech is upping its bet on a PD-L1xVEGF-A bispecific, paying $800 million upfront to buy its Chinese partner Biotheus and secure full rights to a leading prospect in the white-hot immuno-oncology space.
https://www.fiercebiotech.com/biotech/biontech-pays-800m-take-control-potential-keytruda-killer
November 14, 2024 - In today's business development news, Merck (NYSE Symbol: MRK), for example, is reported paying more than 10 times as much for a bispecific molecule that has only just begun human testing.
November 13, 2024 - "As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in acquiring external products with the potential to launch in the near term. Meanwhile, those pharmas facing greater generic threats in the coming decade may be more inclined to pick up earlier-stage candidates from beyond their own pipelines."
"In the coming years, Bristol Myers Squibb, Merck, Amgen, Novartis and AstraZeneca are staring down the greatest level of exposure to generic and biosimilar competition while Vertex, Gilead Sciences, Sanofi, Novo Nordisk and Eli Lilly are the least exposed over the 2025-2030 timeframe, Leerink said."
"The overall message of the report is clear: “Companies with sizable LOE exposure in 2025-2030 are under pressure to acquire assets that can be launched in coming years,” while “[t]hose which do not face significant LOEs until 2030+ may be more aggressive acquirers of earlier-stage assets.” "
https://www.fiercepharma.com/pharma/bms-merck-amgen-and-more-must-pursue-ma-offset-looming-patent-lapses-leerink